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Clinical pathways and the commodiﬁcation of total joint replacementTotal hip replacement (THR) was developed in the 1960s and
entered routine use for disabling advanced hip arthritis in the
mid 1970s1. Total knee replacement (TKR) development and imple-
mentation followed about a decade later2. The early years of hip
and knee replacement use were characterized by innovation in
implant design and in pre-, intra- and postoperative management,
with attendant improvements in perioperativemortality, complica-
tion rates and functional outcomes. Total joint replacements (TJRs)
were performed largely in referral centers during these early years,
by pioneers in the ﬁeld. Operative and perioperative care philoso-
phies and practices differed among surgeons and centers, reﬂecting
the culture of innovation and specialization that typiﬁes new tech-
nologies. Borrowing terminology from retail sales, THR and TKR
represented specialty items offered in boutique settings.
Let’s fast forward about 25 years and note how times have
changed: THR and TKR are now performed in hospitals large and
small by high- and low-volume providers3,4. In fact, in many metro-
politanareas (includingours), patients seekingTHRorTKRcanchoose
from 10 or more centers located within 15 miles of their homes.
Patients often spend as few as 2 days in the hospital. An industry
has developed to provide inpatient and outpatient rehabilitative TJR
care. Reimbursement forTJR isnowcapitated inmanysettings around
theworld, with ﬁxed global payments allotted for each patient to pay
for all pre-, peri- and postoperative components of TJR care. Increas-
ingly, outcomes of care aremonitored todocument and improve rates
of complications. In short, TJR has evolved from a boutique product to
amedical commodity – awidely available product offered by a broad
range of providers at highly competitive prices.
Boutique specialty goods are distinguished by the unique differ-
ences among a small set of providers. Prices tend to be high in rela-
tion to actual inputs because demand exceeds supply and it is
difﬁcult for new providers to enter the marketplace. Commodities,
on the other hand, are offered by many producers and are priced
much more competitively. As TJR assumes more of a commodity
than a boutique phenotype, the organizations that succeed will
be those that master the efﬁcient provision of high-quality TJR
services to large numbers of patients at low cost.
Healthcare organizations have struggled to develop models of
care delivery that meet the dual objectives of efﬁciency and quality.
In this setting, the work of Marshall et al. is especially noteworthy.
These investigators report a large randomized comparative effec-
tiveness trial evaluating a new, evidence-informed, clinical
pathway (NCP) vs standard of care (SOC) for total hip and knee
arthroplasty in three health regions in Alberta, Canada. The goal
of their work was to test a program designed to control escalating
healthcare costs while maintaining quality of care. The intervention1063-4584/$ – see front matter  2012 Osteoarthritis Research Society International. Pu
http://dx.doi.org/10.1016/j.joca.2012.04.024provided dedicated resources for patient intake, operating room
and inpatient care; algorithmic guidelines for the pre-, intra- and
postoperative processes of care; and measurable benchmarks that
allowed for the evaluation and improvement of the process.
Previouswork5 suggesteda4%cost savingsutilizing thenewclin-
ical pathway, largely based on reduced OR time and length of inpa-
tient stay. The trial went a step further to include patient-reported
outcomes at 3 and 12 months. The study designwas rigorous, using
cluster randomization (at the surgeon level) to minimize contami-
nationwithin surgeonpractices. Theprimaryoutcomesused to eval-
uate effectiveness were total Western Ontario and McMaster
Osteoarthritis Index (WOMAC) score improvements at 3 and 12
months after surgery; secondary measures included improvement
in SF-36 scores for physical function (PF) and bodily pain.
Randomization appears to have succeeded in achieving balance
between the NCP and SOC groups. Twelve-month mean WOMAC
scores improved from baseline by 37.5 and 34.5 points in the NCP
and SOC groups, respectively. These are large differences, amount-
ing to approximately two standard deviations. Similarly impressive
Improvements were noted in the SF-36 PF and body pain scores.
The treatment effect of the NCP (deﬁned as improvement between
baseline and 12 months in the NCP group minus improvement in
the SOC group) was 2.56 (95% CI 1.1, 4.0) for the WOMAC, 1.88 for
the SF-36 PF, and 3.01 for bodily pain.
Adverse events for all groups were low. However, for the NCP
patients, the most frequently reported adverse event was hip dislo-
cation, and at 1.1%, this was higher than historical rates (0.7%) and
higher than in the SOC group (0%).
The authors conclude that hip and knee replacements are effec-
tive surgical procedures that were further improved by use of the
accelerated NCP approach. The effect of the NCP was small in
comparison to the dramatic effect of the surgery itself. The treat-
ment effect was about three points whereas the minimal clinically
important change is closer to 10 points. But even this small gain in
patient-reported outcomes over the SOC is noteworthy when
viewed in the context of an overall reduction in inpatient costs.
As with all good studies, this one raises questions that will need
to be addressed in further work. Did the results arise as a chance
ﬁnding?Were the functional differences observedhere sustainable?
The study will need to be conﬁrmed and the differences in short-
term patient-reported outcomes will need to be evaluated over
longer follow-up. Are the small differences in dislocation rate
a robust ﬁnding? The initial cost savings of the NCP group could be
offset by subsequent revisions if the higher hip dislocation rates
reported in the NCP group here eventuate in higher rates of implant
failure. Did the effects of the intervention arise fromspeciﬁc changesblished by Elsevier Ltd. All rights reserved.
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ciency prompted by the care improvement intervention? Interven-
tions have the opportunity to both introduce speciﬁc process
changes that themselves result in improvedoutcomes, and to inspire
changes in the overall care environment that then translate into
betteroutcomes. Are the system improvements studied in this paper
translatable to other health care settings? To other procedures in the
same settings? This evaluation model certainly merits further eval-
uation across a range of settings, particularly when policymakers
across theworld are so eagerly searching forways to reducemedical
costs without compromising the quality of patient care.
The Alberta team’s work in this area points to the potential
beneﬁts of the transformation toward commodiﬁcation of TJR.
The heterogeneity in care processes that characterized the boutique
era of TJR development is potentially costly from the standpoint of
both dollars and outcomes. Standardization of evidence-based
practices has the potential to yield economic and patient-
centered beneﬁts. Patients, providers, payers and health systems
all stand to gain if the ﬁndings of this RCT from Alberta are
conﬁrmed and integrated into clinical practice and policy.
Author contributions
Drs. Katz and Martin both contributed to the conceptualization,
writing and editing of the piece.
Funding support
Supported in part by NIH/NIAMS Grant P60 AR 47782.
Conﬂict of interest
Neither Dr. Katz nor Dr. Martin has a conﬂict of interest.
Acknowledgments
The work is funded in part by NIH/NIAMS AR 47782. NIAMS had
no role in the work. The authors appreciate the editorial assistance
of Julian Prokopetz, BA.References
1. Harris WH, Sledge CB. Total hip and total knee replacement (1).
N Engl J Med 1990;323:725–31.
2. Harris WH, Sledge CB. Total hip and total knee replacement (2).
N Engl J Med 1990;323:801–7.
3. Katz JN, Losina E, Barrett J, Phillips CB, Mahomed NN, Lew RA,
et al. Association between hospital and surgeon procedure
volume and outcomes of total hip replacement in the United
States medicare population. J Bone Joint Surg Am 2001;83-A:
1622–9.
4. Katz JN, Mahomed NN, Baron JA, Barrett JB, Fossel AH, Creel AH,
et al. Association of hospital and surgeon procedure volume
with patient-centered outcomes of total knee replacement in
a population-based cohort of patients age 65 years and older.
Arthritis Rheum 2007;56:568–74.
5. Alberta Bone and Joint Health Institute. Hip and Knee Joint
Replacement Project Evaluation Report. Calgary: Alberta Health
and Wellness; 2006.J.N. Katzyz*, T.L. Martinyx
yDepartment of Orthopedic Surgery, Harvard Medical School, Boston,
MA, USA
zDivision of Rheumatology, Immunology and Allergy, Harvard Medical
School, Boston, MA, USA
xBrigham and Women’s Hospital, Boston VA Medical Center, Harvard
Medical School, Boston, MA, USA
* Address correspondence and reprint requests to: J.N. Katz,
Orthopedic and Arthritis Center for Outcomes Research, Brigham
and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA.
Tel.: 1-617-732-5338; Fax: 1-617-525-7900.
E-mail address: jnkatz@partners.org (J.N. Katz)
